Search This Blog

Monday, March 2, 2026

United Therapeutics' phase 3 trial of oral PAH therapy ralinepag meets primary endpoint

 

 with 55% risk reduction

  • United Therapeutics plans to submit an NDA to the FDA by the second half of 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)